Latest Breaking News On - Transform patient - Page 5 : comparemela.com

Marshfield Clinic Health System and Notable Announce System-Wide Deployment of Intelligent Automation to Transform Patient and Staff Engagement

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Bristol-Myers Squibb (BMY) Reports Positive CHMP Opinion for Once-Daily Sotyktu

Equality Health Chief Medical Officer to Present at MGMA Leaders Conference

/PRNewswire/ Equality Health, a leading provider of value-based physician networks uniquely equipped to address the needs of diverse and historically.

Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Effica

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong.